Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285694 · ClinicalTrials.gov registry record · Phase 1
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Arsenal Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 3
- Study locations
NCT07285694 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Arsenal Biosciences. The registered enrollment target is 190 participants, below the 401-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07285694, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Arsenal Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Conditions Studied
Interventions
- BIOLOGICAL AB-3028
Study Locations (3)
California
- City of Hope - Duarte
Iowa
- University of Iowa and Holden Comprehensive Cancer Center - Iowa City
New York
- Perlmutter Cancer Center - NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2031-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285694
The ClinicalTrials.gov registry entry for NCT07285694 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (53% lower). The listed sponsor is Arsenal Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which AB-3028 is the first listed.
NCT07285694 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT07285694 about?
NCT07285694 is a clinical study titled "AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)". This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT07285694?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2026-01-09. Estimated completion is 2031-05.
What conditions does trial NCT07285694 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT07285694?
The interventions under investigation include: AB-3028 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07285694?
This trial is sponsored by Arsenal Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285694 being conducted?
This trial has 3 study locations across California, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
RECRUITING · Phase 1
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.